Sessiz Tehdit: Konnektif Doku Hastalıklarında Pulmoner Hipertansiyonun Tanı ve Takibi

Öz

Konnektif doku hastalıkları (KDH), sistemik doğaları nedeniyle birçok organda ciddi komplikasyonlara yol açabilmektedir. Bu komplikasyonların en önemlilerinden biri pulmoner hipertansiyon (PH)’dur. PH, erken evrelerde sessiz seyretmesi nedeniyle tanıda gecikmelere yol açan, ilerleyen dönemlerde ise yüksek mortalite ile ilişkili olan ciddi bir klinik tablodur. Bu derlemede, KDH’ye bağlı pulmoner hipertansiyonun patofizyolojisi, klinik özellikleri, tanı yöntemleri ve güncel takip stratejileri literatür ışığında ele alınmış, ayrıca tartışma bölümünde güncel araştırmalar ve geleceğe yönelik beklentiler değerlendirilmiştir.

Anahtar Kelimeler

• Pulmoner hipertansiyon
• Konnektif doku hastalıkları
• Sistemik skleroz

Silent Threat: Diagnosis and Follow-Up of Pulmonary Hypertension in Connective Tissue Diseases

Öz

Connective tissue diseases , due to their systemic nature, can lead to severe complications in multiple organs. One of the most significant of these complications is pulmonary hypertension . Pulmonary hypertension is a serious clinical condition that, because of its silent course in the early stages, often leads to delays in diagnosis and, in later stages, is associated with high mortality. In this review, the pathophysiology, clinical features, diagnostic methods, and current follow-up strategies of CTD-related pulmonary hypertension are discussed in the light of the literature, and the discussion section further evaluates recent research and future perspectives.

Anahtar Kelimeler

• Pulmonary hypertension
• Connective tissue diseases
• Systemic sclerosis

Kaynakça

1. Referans 1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731.
2. Referans 2. Galiè N, Simonneau G, Barbera JA, Beghetti M, Corris P, Ghofrani A, et al. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1):1802148.
3. Referans 3. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699.
4. Referans 4. Dong Y, Pan Y, Wang R, Wu Y, Ban C, He Y. Prognostic value of cardiac magnetic resonance–derived right ventricular remodeling parameters in pulmonary hypertension: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2020;13(1):010568.
5. Referans 5. Chen HA, Hsu TC, Yang HF, Sung YT, Chou YM, Luo SF, et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther. 2019;21:82.
6. Referans 6. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340–1349.
7. Referans 7. Sarı A, Satış H, Ayan G, Küçükşahin O, Kalyoncu U, Fidancı AA, et al. Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study. Clin Rheumatol. 2024; 43(6):1919-1925.
8. Referans 8. Montani D, Lau EMT, Dorfmüller P, Girerd B, Jais X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518–1534.

9. Referans 9. Thakkar V, Stevens WM, Prior D, Youssef P, Liew D, Proudman S. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case–control study. Arthritis Res Ther. 2012;14:143.
10. Referans 10. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension (AMBITION). N Engl J Med. 2015;373(9):834–844.
11. Referans 11. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension (SERAPHIN). N Engl J Med. 2013;369(9):809–818.
12. Referans 12. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension (GRIPHON). N Engl J Med. 2015;373(26):2522–2533.
13. Referans 13. González-López L, Cardona-Muñoz EG, Celis A, García-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus: a randomized controlled trial. Lupus. 2004;13(2):105–112.
14. Referans 14. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013; 24;62.
15. Referans 15. Düzgün Z, Kayıkçıoğlu LM, Aktan Ç, Bara B, Eroğlu FZ, Yağmur B, et al. Decreased circulating microRNA-21 and microRNA-143 are associated to pulmonary hypertension. Turk J Med Sci. 2023; 53(1):130-141.
16. Referans 16. Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger TA, Pinckney A, et al. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis–associated pulmonary arterial hypertension: a randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021;204(2):209–221.
17. Referans 17. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease (SENSCIS). N Engl J Med. 2019;381(18):1595–1607.
18. Referans 18. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension (PULSAR). N Engl J Med. 2021;384(13):1204–1215.
19. Referans 19. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension (STELLAR). N Engl J Med. 2023;388(16):1478–1490.
20. Referans 20. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (from the REVEAL registry). Circulation. 2015;132(25):2403–2411.
21. Referans 21. Alabed S, Shahin Y, Garg P, Johns CS, Lewis RA, Capener D, et al. Cardiac MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. Open Heart. 2021;8(2):001558.
22. Referans 22. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337.